Prexasertib

Generic Name: Prexasertib

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₇O_₂

CAS Number: 1234015-52-1

Unique Ingredient Identifier: 820NH671E6

Background: Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, breast cancer, and Ovarian Cancer, among others.

Clinical Trials

A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Gemcitabine
Drug: ACR-368

First Posted Date: 2024-09-19

Last Posted Date: 2024-10-01

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 43

Registration Number: NCT06597565

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

Phase 1

Recruiting

Conditions: Endometrial Adenocarcinoma
Urothelial Carcinoma
Platinum-resistant Ovarian Cancer

Interventions: Drug: ACR-368
Diagnostic Test: OncoSignature
Drug: Gemcitabine

First Posted Date: 2022-09-21

Last Posted Date: 2025-04-15

Lead Sponsor: Acrivon Therapeutics

Target Recruit Count: 390

Registration Number: NCT05548296

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States

and more 64 locations

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Phase 1

Completed

Conditions: Desmoplastic Small Round Cell Tumor
Rhabdomyosarcoma

Interventions: Drug: Prexasertib
Drug: Irinotecan

First Posted Date: 2019-09-19

Last Posted Date: 2025-02-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT04095221

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Phase 1

Completed

Conditions: Brain Tumor, Refractory
Brain Cancer
CNS Cancer
Brain Tumor
CNS Tumor
Medulloblastoma, Non-WNT/Non-SHH
CNS Neoplasm
Brain Tumor, Recurrent
Medulloblastoma
Medulloblastoma Recurrent

Interventions: Drug: Prexasertib
Drug: Cyclophosphamide
Drug: Gemcitabine
Biological: filgrastim
Biological: peg-filgrastim

First Posted Date: 2019-07-17

Last Posted Date: 2025-02-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 21

Registration Number: NCT04023669

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions: Drug: Prexasertib
Drug: Mitoxantrone
Drug: Etoposide
Drug: Cytarabine

First Posted Date: 2018-11-08

Last Posted Date: 2019-06-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03735446

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: LY3300054
Drug: Prexasertib

First Posted Date: 2018-04-12

Last Posted Date: 2021-04-15

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 17

Registration Number: NCT03495323

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Prexasertib

First Posted Date: 2018-01-29

Last Posted Date: 2022-08-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 172

Registration Number: NCT03414047

Locations: 🇺🇸
Kaiser Permanente Medical Center, Vallejo, California, United States
🇬🇧
Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
🇺🇸
University of Southern Florida School of Medicine, Gainesville, Florida, United States

and more 43 locations

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Prexasertib
Drug: Olaparib

First Posted Date: 2017-02-17

Last Posted Date: 2021-09-02

Lead Sponsor: Geoffrey Shapiro, MD, PhD

Target Recruit Count: 29

Registration Number: NCT03057145

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Phase 2

Completed

Conditions: Advanced Cancers

Interventions: Drug: LY2606368

First Posted Date: 2016-08-22

Last Posted Date: 2022-10-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 27

Registration Number: NCT02873975

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Advanced Cancer
Metastatic Cancer
Colorectal Cancer
Non-small Cell Lung Cancer

Interventions: Drug: prexasertib
Drug: ralimetinib

First Posted Date: 2016-08-09

Last Posted Date: 2018-12-14

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 9

Registration Number: NCT02860780

Locations: 🇺🇸
Carolinas Medical Center, Charlotte, North Carolina, United States
🇺🇸
Sarah Cannon Research Institute SCRI, Nashville, Tennessee, United States
🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Köln, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy